Location:Home > News > news

March 21, 2017
    Tarrex Biopharma has received approval from the US Food and Drug Administration for its Investigational New Drug Application (IND) for TX803. Tarrex is planning to conduct phase I clinical studies with TX803 in refractory metastatic colorectal cancer patients at Dana Farber Cancer Institute.

December 5, 2016
     Tarrex Biopharma has submitted an Investigational New Drug application to the US Food and Drug Administration, to conduct phase I clinical investigations on TX803 in the United States. 

November 25, 2016

   Tarrex Biopharma has received Notification on Grant of Patent Right for Invention from the State Intellectual Property Office of the People's Republic of China, as well as Notice of Allowance from the United States Patent and Trademark Office (USPTO) for TX803 related patent.

January 29, 2016
    Tarrex Biopharma is pleased to announce that Kimmie Ng, MD, MPH, has agreed to serve as Tarrex’s clinical consultant. Dr. Kimmie Ng is the Director of Clinical Research, Gastrointestinal Cancer Center, Physician at Dana Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School.Dr. Kimmie Ng has extensive experience in treatment and prevention trials in colorectal cancer, and has more than 50 publications, reviews, or book chapters.

November 3, 2015

     Tarrex Biopharma Ltd announces that it is investing in Aranda Pharma Ltd of Finland with a 33% stake. The two small biopharma companies will be co-developing Aranda’s androgen receptor (AR) antagonist for the treatment of Castration Resistant Prostate Cancer(CRPC).  Aranda’s AR antagonist has demonstrate defficacy in cellular and animal models of prostate cancer that are resistant to current treatment options. Tarrex and Aranda will jointly advance the program through preclinical and early clinical development for the global market.


October 16, 2015

      Tarrex Biopharma received “Outstanding Company” award in the Fourth “China Innovationand Entrepreneurship Competition”